Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial - PubMed
4 hours ago
- #PDE4 inhibitor
- #Behçet's syndrome
- #clinical trial
- Study evaluated mufemilast, a PDE4 inhibitor, in Behçet's syndrome patients with active oral ulcers.
- Randomized trial with 90 patients assigned to mufemilast (45 mg, 60 mg) or placebo for 12 weeks.
- Primary endpoint: AUC for oral ulcers from baseline to week 12.
- Mufemilast significantly reduced oral ulcers and improved pain scores vs. placebo (P < .001).
- Safety profile was acceptable with transient PDE4-related side effects and low discontinuation rates.
- No serious adverse events related to mufemilast were reported.